Articles in this Issue

  • Lyophilization – It’s Not Just for Food Preservation Anymore

    Ed Price
    From the earliest civilizations to astronauts in space, drying out food to preserve it and retain vital nutrients has been a common practice. Today, the same fundamental strategy of lyophilization is becoming a key method used by drug and medical device manufacturers for the development of polymers used in medical devices and for drug delivery.
  • Successful Early-Phase Development of mAb Drugs

    Narine Baririan, PharmD, Bruno Speder
    The first FDA-approved therapeutic monoclonal antibody (mAb) was muromonab in 1986, and since then, numerous mAb drugs have been approved, and many more are in the later stages of clinical development. In the main, mAbs are being developed against immunological and oncological targets, but their beneficial characteristics allow development of drugs for various therapeutic indications.
  • A Reborn CDMO Helping Partners Navigate the Product Development Continuum

    Pharmaceutics International Inc (Pii) is returning to its contract development and manufacturing organization (CDMO) foundation in order to help partners navigate product development from beginning to end.
  • Model for Qualification of Shipping Systems for Temperature Sensitive Pharma Products

    Zvonimir Majic PhD, Erik J. van Asselt, PhD, Rafik H. Bishara, Ph.D., Eric Stener
    Temperature sensitive pharmaceutical products should be transported under temperature-controlled conditions in order to maintain product quality using a Qualified Shipping System (QSS).
  • Exploring the Role of Embedded CDMOs in Outsourcing

    Joy L Silva
    Pharmaceutical companies are looking for outsourcing partners with the necessary equipment, facilities, expertise and resources they need to avoid common manufacturing pitfalls that may prevent the success of their drug.
  • Look for Regulators to Appease Worried Consumers in 2020

    Chris Harvey
    As the FDA moves into 2020, the agency is facing some hot button issues it failed to put to rest in 2019. Issues including NDMA, e-cigarettes and vaping, medical marijuana, the unregulated use of CBD oils, and asbestos in talc are all on the table.
  • The Clinical Trial Site and the CRO: Creating a Powerful Partnership

    Dr. Stephen Gately
    Ringing in the new year with headlines about cancer deaths declining was a great way to start 2020 and celebrate the many innovative advancements pushing the industry forward.
  • Global Air Cargo Trends Re-Shaping Pharmaceutical Transport

    Dominic Hyde
    As we welcome the new decade and the exciting advances it is expected to unleash, many of the forces that shaped the past decade for transporting pharmaceuticals will continue. Price pressures, alternatives to air freight and increasing automation are just a few. However, there are emerging trends that make 2020 unique.
  • Combating Rising Competition for Qualified Safety Professionals

    Alan White
    The challenge of retaining talent in life sciences, not least in safety and regulatory fields, has arguably never been higher up the list of industry conversation topics than now. This is particularly the case as younger professionals’ ambitions for a broad base of experience conflict with companies’ needs to hang onto the expertise they have invested in. The challenge is acute in safety/quality and regulatory areas. Here, companies’ ability to achieve and retain the optimum depth of skills and experience is continuously threatened by employees’ ambitions to build rounded CVs, and keep their work interesting - by trying out a range of roles.
  • Facilitating Supply Chain Collaboration with Blockchain Technology

    Jason Lacombe
    With the introduction of serialization regulations and the prioritization of end-to-end visibility, the digitization of global supply chains is beginning to take center stage.
  • An Interview with… Paul Moravek

    Moravek, Inc. is a leading provider of custom radiolabeled, stable labeled and non-labeled compounds and specializes in the manufacture and release of carbon-14 labeled APIs under cGMP conditions in support of clinical trials worldwide.
  • HORIZON LINES: A Quarterly Review of NDAs – October-December, 2019

    This quarterly review of new drug applications contain data for applications approved for the first time during the fourth quarter of 2019 which includes New Molecular Entities (NMEs) and new biologics.
  • <<
  • >>